Comparative Pharmacology
Head-to-head clinical analysis: TECHNETIUM TC 99M MERTIATIDE KIT versus TECHNETIUM TC 99M MEBROFENIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TECHNETIUM TC 99M MERTIATIDE KIT versus TECHNETIUM TC 99M MEBROFENIN.
TECHNETIUM TC 99M MERTIATIDE KIT vs TECHNETIUM TC-99M MEBROFENIN
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Technetium Tc 99m mertiatide is a radiopharmaceutical diagnostic agent that undergoes renal tubular secretion and glomerular filtration, allowing for dynamic imaging of renal function and urinary tract patency.
Technetium Tc-99m mebrofenin is a radiopharmaceutical that, after intravenous administration, is taken up by hepatocytes and excreted into the biliary system. It allows scintigraphic imaging of the liver and biliary tract by emitting gamma rays detectable by a gamma camera.
FDA: Renal imaging, including evaluation of renal perfusion, renal function, and urinary tract obstruction.Off-label: Assessment of renal transplant function, detection of renovascular hypertension.
Hepatobiliary imaging (cholescintigraphy) to evaluate liver and gallbladder functionAid in the diagnosis of acute cholecystitisAssessment of biliary obstructionEvaluation of biliary leakage
"The serum concentration of Teriflunomide can be increased when it is combined with Technetium Tc-99m mebrofenin."
"The serum concentration of Eltrombopag can be increased when it is combined with Technetium Tc-99m mebrofenin."
1-10 mCi (37-370 MBq) intravenously as a single dose for renal imaging.
Adults: 1-5 mCi (37-185 MBq) IV bolus. Image immediately and at intervals up to 60 minutes for hepatobiliary scintigraphy.
None Documented
None Documented
Terminal elimination half-life: approximately 1.5–2 hours for the non-protein-bound fraction; allows rapid imaging within 30 minutes and clearance from blood pool.
Terminal elimination half-life: approximately 6 hours (range 4-8 hours) in patients with normal hepatic function. In obstructive jaundice, half-life may be prolonged due to delayed biliary excretion.
Not metabolized; excreted unchanged primarily by the kidneys via glomerular filtration and tubular secretion.
Technetium Tc-99m mebrofenin is primarily taken up by hepatocytes and excreted unchanged into the bile. No significant metabolism occurs.
Renal: approximately 50% excreted unchanged in urine within 2 hours; 70% within 24 hours. Biliary/fecal: negligible.
Primarily biliary (hepatobiliary) excretion: ~75% of administered activity is excreted into bile and subsequently into feces within 24 hours. Renal excretion accounts for <10% of the administered dose.
Approximately 50% bound to plasma proteins, primarily albumin.
Approximately 90% bound to serum albumin and other plasma proteins.
Volume of distribution: approximately 0.3 L/kg (range 0.2–0.4 L/kg), reflecting distribution into extracellular fluid and renal tissue.
Approximately 0.3 L/kg, indicating distribution primarily within the extracellular fluid space and hepatobiliary system.
Not applicable (administered only intravenously); bioavailability 100% by IV route.
Only administered intravenously; bioavailability is 100% by IV route; no oral bioavailability data as it is not administered orally.
No dose adjustment required; however, image quality may be affected in severe renal impairment (GFR <30 mL/min).
No dosage adjustment required for impaired renal function; drug is primarily hepatobiliary excreted.
No dose adjustment needed; not hepatically metabolized.
Contraindicated in severe hepatic impairment (Child-Pugh class C); consider alternative imaging. For Child-Pugh class B, use lowest effective dose (1 mCi) with extended imaging protocol.
0.05-0.15 mCi/kg (1.85-5.55 MBq/kg) intravenously, minimum 0.3 mCi (11.1 MBq).
Children: 0.05 mCi/kg (0.05 mCi/kg, minimum 0.5 mCi) IV, not to exceed 5 mCi total.
No specific dose adjustment; use lowest effective dose due to potential decreased renal function.
No specific dose adjustment required; use lowest effective dose (1-2 mCi) due to potential comorbidities and prolonged imaging time.
None.
None.
["Risk of allergic reactions including anaphylaxis.","Use caution in patients with severe renal impairment due to reduced clearance.","Pregnancy: Consider risk vs benefit; radiation exposure to fetus.","Lactation: Interrupt breastfeeding for 24 hours post-dose."]
["Radioactive material; use appropriate shielding and handling precautions","Risk of allergic or hypersensitivity reactions","Caution in patients with severe hepatic impairment as scan quality may be compromised","Use in pregnancy only if clearly needed; consider risk to fetus","Lactation: interrupt breastfeeding for a period adequate to allow decay of radioactivity"]
["Known hypersensitivity to any component of the kit.","Not indicated for use in patients with known or suspected pregnancy unless benefit clearly outweighs risk."]
["Known hypersensitivity to technetium Tc-99m mebrofenin or any component of the formulation"]
Data Pending Review
Data Pending Review
No specific food interactions. Maintain adequate hydration before and after administration.
Fasting for 4-6 hours prior to injection is required to promote gallbladder filling. Avoid fatty meals before the study as they may cause gallbladder contraction and interfere with visualization. No known food interactions after the procedure.
Technetium Tc 99m mertiatide is a radiopharmaceutical. In pregnancy, radiation exposure to the fetus is a concern. First trimester: highest risk for teratogenesis; use only if benefit outweighs risk. Second and third trimesters: lower risk, but cumulative radiation dose should be minimized. No specific teratogenic effects reported; however, theoretical risk of fetal harm exists due to radiation.
Technetium TC-99M mebrofenin is a radiopharmaceutical. Fetal radiation exposure depends on gestational stage. First trimester: highest risk of teratogenesis, including CNS malformations and growth restriction, with a threshold of approximately 100 mGy. Second and third trimesters: increased risk of childhood cancer with a linear no-threshold model. Estimated fetal dose for a typical 185 MBq (5 mCi) administration is ~10 mGy, below the 100 mGy threshold for malformations, but attributable risk for childhood leukemia is estimated at 1 in 6000. All trimesters: consider alternative imaging without ionizing radiation when possible.
Technetium Tc 99m mertiatide is excreted in breast milk. The M/P ratio is not established. Breastfeeding should be interrupted for at least 24-48 hours after administration to minimize infant radiation exposure. Pump and discard milk during this period.
Technetium-99m has a physical half-life of 6.02 hours. In breast milk, activity peaks at 2-12 hours. The milk-to-plasma ratio for Tc-99m mebrofenin is not specifically reported but for Tc-99m pertechnetate M/P ratio is 4.5. For mebrofenin, assumed similar. Interruption of breastfeeding for 24-48 hours after administration is recommended. Complete cessation may be considered, but minimal risk after 48 hours.
Standard adult dose (1-10 mCi IV) may be used in pregnancy if indicated. No specific dose adjustment recommended based on pharmacokinetic changes in pregnancy; however, minimize radiation dose by using the lowest necessary activity consistent with obtaining diagnostic information. Increased renal clearance in pregnancy may affect imaging timing but does not require dose adjustment.
No dose adjustment required based on pregnancy-induced pharmacokinetic changes alone. However, the lowest possible dose consistent with diagnostic information should be used. Non-ionizing alternatives (e.g., ultrasound, MRI) should be considered first. If necessary, use 185 MBq (5 mCi) as standard adult dose; no evidence of altered clearance in pregnancy.
Category C
Category C
Technetium Tc 99m mertiatide is a renal tubular imaging agent used for dynamic renal scintigraphy. Ensure adequate hydration before and after injection to promote clearance. Image acquisition timing is critical: typically 1-3 seconds per frame for perfusion phase and 10-30 seconds for function phase. Use caution in patients with severe renal impairment as delayed visualization may occur. Do not administer if solution contains particulate matter or discoloration.
Tc-99m mebrofenin is a hepatobiliary imaging agent. Key pearls: (1) Administer IV slowly; (2) Morphine augmentation (0.04 mg/kg IV) may be used to improve biliary tract visualization if gallbladder not seen by 60 min, but ensure no contraindications; (3) Delayed imaging up to 4 hours may be needed; (4) Bilirubin >10 mg/dL severely impairs hepatic uptake; (5) Premedication with sincalide (0.02 mcg/kg IV over 30 min) may be used to empty gallbladder prior to study.
You will receive an injection of a radioactive tracer that allows us to take pictures of your kidneys.Drink plenty of water before and after the test to help flush the tracer out of your body.The radiation exposure is minimal and comparable to a standard X-ray.You may need to empty your bladder before and during the imaging procedure.Notify the technologist if you are pregnant, breastfeeding, or have any allergies.
This is a radioactive tracer used to scan your gallbladder and bile ducts.You will receive an injection into a vein, and images will be taken over 1-4 hours.You may be asked to fast for 4-6 hours before the test, but you can drink water.Tell your doctor if you are pregnant, breastfeeding, or have any allergies.Drink plenty of water after the scan to help eliminate the tracer from your body.